Original Report

Impact of bladder volume on radiation dose to the rectum in the definitive treatment of prostate cancer


 

Background and objective Our group created and routinely reviewed a dedicated prostate intensity-modulated radiation therapy (IMRT) delivery program. Previously, a retrospective review of our experience demonstrated that a larger bladder volume reduced radiation dose to the rectum. We conducted an observational study to confirm this relationship.

Methods Men receiving definitive radiation for prostate cancer were eligible for the study. Eligible patients received 2 computed axial tomography (CT) scans on the day of their planning CT scan: 1 with a full bladder and 1 with an empty bladder. On each CT data set, the prostate, rectum, bladder, penile bulb, and femoral heads were contoured. 2 IMRT plans were completed on each dataset: 1 by a medical dosimetrist and 1 by a medical physicist. The study plans targeted the prostate to 79.2 Gray (Gy) while respecting predefined dose tolerances to the other contoured structures. Rectal doses were compared on empty and full bladder CT data sets.

Results From June 29, 2010 to December 14, 2011, 17 full bladder data sets and 15 empty bladder data sets were available for analysis. Median change in bladder volume was 63 ml. Full vs empty bladder set-up was associated with a statistically significant reduction in the mean rectal dose of 25.41 Gy vs 27.6 Gy (P = .031).

Limitations Small sample size and small variations in bladder volumes.

Conclusions A greater bladder volume resulted in a reduced mean dose to the rectum irrespective of planning method.

Funding/sponsorship None

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

AUA: Renal mass biopsy trend tied to nonsurgical RCC treatment
MDedge Hematology and Oncology
Urine assay ruled out high-grade prostate cancer
MDedge Hematology and Oncology
Isolated splenic metastasis in a patient with two distinct genitourinary malignancies
MDedge Hematology and Oncology
Cardiovascular disease in oncology
MDedge Hematology and Oncology
Study finds sharp increase in active surveillance for low-risk prostate cancer
MDedge Hematology and Oncology
ASCO 2015: from data and learning, to daily practice
MDedge Hematology and Oncology
Harnessing new data on immunotherapies
MDedge Hematology and Oncology
Short-term CVD risk rises with testicular cancer chemotherapy
MDedge Hematology and Oncology
Docetaxel added to ADT extends survival from prostate cancer
MDedge Hematology and Oncology
Adding trebananib increased toxicity for metastatic RCC patients
MDedge Hematology and Oncology